JOINT PHARMACEUTICAL SUPPLIER MEETING & WHO PREQUALIFICATION OF MEDICINES PROGRAMME

Global Drug Facility

Paloma Marroquin Lerga
Technical officer
24 – 26 September 2012
ROLE OF GDF

- Public Sector procurement of TB drugs, of the right quality, in the right quantity, at the right price, and deliver them at the right time to the right people

- Provide **Technical Assistance** by monitoring PSM in countries utilising GDF’s services and highlight system strengthening requirements.
GDF PROCUREMENT PROCESS

• Expressions of interest for TB manufacturers issued jointly by GDF and Global Fund.

• Competitive bidding process conducted by GDF. Bids issued to prequalified manufacturers (site and product). Fair, transparent, quality, best value for money.

• Public bid opening.

• Commercial evaluation: price, delivery period, production capacity, manufacturer’s geographic location, minimum batch quantity, reliability.

• Contract award – long term agreements (LTA) implemented to multiple suppliers for the same products to avoid monopolies/ensure timely deliveries.
Trends in GDF Procurement

- **2007**: $19 Million
- **2008**: $35 Million
- **2009**: $48 Million
- **2010**: $48 Million
- **2011**: $51 Million

- **2007**: $24 Million
- **2008**: $45 Million
- **2009**: $74 Million
- **2010**: $87 Million
- **2011**: $132 Million

- **2007**: $43 Million
- **2008**: $83 Million
- **2009**: $103 Million
- **2010**: $132 Million
- **2011**: $155 Million
Business Volume 2011

- FLD, $56,511,227
- MDR, $85,291,452
- New Diag, $6,405,667
- GeneXpert, $6,489,297
Top 10 FLD’s 2011

- **2-FDC/RH-60/30**, $681,124
- **Water for injection-5**, $594,720
- **Diagnostics Kit**, $1,297,848
- **3-FDC/RHE-150/75/275**, $1,675,667
- **Category II Kit**, $1,297,848
- **Category II Kit A2**, $2,530,592
- **Streptomycin**, $3,498,162
- **Category I & III Kit A**, $3,722,060
- **2-FDC/RH-150/75**, $8,014,635
- **4-FDC/RHZE-150/75/400/275**, $11,125,987
Top 10 SLD’s 2011

- Cycloserine, 27,943,196
- PAS (acid), 14,114,420
- Capreomycin, 10,522,306
- Kanamycin, 8,247,057
- Prothionamide, 3,131,455
- PAS (sodium), 3,260,541
- Moxifloxacin, 2,285,282
- Levofloxacin, 2,024,491
- Ethionamide, 1,920,731
- Amikacin, 2,586,494

PAS (acid) is the largest share, followed by Cycloserine.
GDF Grants

• FLD:
  – Grants by USAID and CIDA
  – Grants by UNITAID for paediatric formulations
  – In 2011, GDF saw a sharp increase in requests for 1st line grants (24 approved 2010 vs 42 approved in 2011).
  – In Q1 2012, GDF launched call for applications (18 grants approved)

• SLD:
  – Grants by UNITAID (MDR-TB project)
# FUNDS FOR TB DRUGS & DIAGNOSTICS

<table>
<thead>
<tr>
<th>Project</th>
<th>2012</th>
<th>2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>FLD (UNITAID paed; USAID; CIDA; others)</td>
<td>USD 29,870,274</td>
<td>USD 6,553,398</td>
</tr>
<tr>
<td>SLD (UNITAID MDRTB)</td>
<td>USD 5,538,254</td>
<td>-</td>
</tr>
<tr>
<td>Diagnostics (UNITAID)</td>
<td>USD 53,220,350</td>
<td></td>
</tr>
</tbody>
</table>
http://www.stoptb.org/gdf/drugsupply/drugs_available.asp

- GDF Product Catalogue
- Quality Assurance Policy
- Procurement Notices
- Documents & Reports
- Procurement and Supply Management (PSM) Tools
- GDF Order Management System
THANK YOU

Paloma Marroquín Lerga
Technical officer
lergap@who.int Tel. +41 22 791 26 12